Kerrie Clerici, Michael Swain, Dominic Fernandez, Julia Schulz, Matthew Archer, Janine Campbell

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Kerrie Clerici, Michael Swain, Dominic Fernandez, Julia Schulz, Matthew Archer, Janine Campbell"

Transcription

1 Minimal Residual Disease (MRD) Testing by Flow Cytometry for childhood Precursor B Cell Acute Lymphoblastic Leukaemia Royal Children s Hospital experience. Kerrie Clerici, Michael Swain, Dominic Fernandez, Julia Schulz, Matthew Archer, Janine Campbell

2 Children s Oncology Group The Children s Oncology Group (COG) studied the prognostic impact of MRD at different time points in a large cohort of patients. Samples at 3 different time points were assessed. Peripheral blood at Day 8 of induction Bone Marrow Aspirate at Day 29 of induction Bone Marrow Aspirate at end of consolidation Borowitz M J et al. Blood 2008; 111(12):

3 Day 8 Day 29 Borowitz M J et al. Blood 2008; 111(12):

4 Prognostic significance of day 8 blood MRD in patients who are MRD negative in bone marrow by day 29 Borowitz M J et al. Blood 2008; 111(12):

5 Prognostic significance of endconsolidation MRD Borowitz M J et al. Blood 2008; 111(12):

6 Multivariate analysis of prognostic factors affecting outcome Variable Hazard ratio P Day 29 MRD>0.01% 4.31 <0.001 NCI risk group 2.25 <0.001 Trisomies 4 and <0.001 Day 8 MRD (PB) >0.01% TEL-AML Day 8 M1 marrow Borowitz M J et al. Blood 2008; 111(12):

7 Overview of the COG AALL08B1 Classification System for B-precursor ALL Risk Group Low Average High Very High Projected 5-yr EFS > 95% 90-95% 75-90% < 75% NCI Risk-Group SR SR SR SR SR HR SR HR Any Favorable Genetics Yes Yes No Yes No Any No Any No Day 8 PB MRD < 0.01% 0.01% < 1.0% Any 1.0% Any Any Any Any Day 29 BM MRD < 0.01% < 0.01% < 0.01% 0.01% < 0.01% < 0.01% >0.01% >0.01% Any Patient number/ year Fraction of patients 14.7% 37.3% 35% 13% Source: Children s Oncology Group, AALL08B1. Classification of Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL). Version 05/28/10

8 Our experience Received a Government New Technology grant in Sept 2010 Visited the COG Flow Cytometry Reference Laboratory in Seattle, Nov 2010 and again in May 2013 Navios, 10 colour flow cytometer arrived in Dec 2010 And so the fun began... We tested our first patient in March 2011 (test in validation phase) We reported our first result in Sept We are now an approved COG reference centre Sept 2015

9 Method Based on COG procedure Stain-then-lyse/fix procedure 1 x 10 6 cells labelled per tube Samples were run on a Navios TM Flow Cytometer (Beckman Coulter) and analysed using Kaluza (Beckman Coulter) software Aimed to collect at least MNC events ( total events) so we can achieve a sensitivity of at least 0.01% Flow Set Pro beads (Beckman Coulter) were used to standardise fluorescent parameters Titrations performed on all antibodies and then each new lot was verified to ensure reproducible fluorescence and optimal staining and compensation check.

10 Panel Fluorochrome Tube 1 Tube 2 Tube 3 (Denominator) Denominator calculation: MRD (T1 or T2) / B cells (T3) (for BM samples) B cells (T1 or T2) / mononuclear cells (T3) Denominator for PB (day 8 samples) is Syto 16 (TNC) Day 8 Tube (PB) FITC / Syto 16 CD20 CD9 Syto 16 Syto 16 PE CD10 CD13 & CD33 CD20 PerCP-Cy5.5 CD38 CD34 CD3 CD34 PC7 CD19 CD19 CD19 CD19 APC CD58 CD10 CD71 CD10 APC-H7 CD45 CD45 CD45 CD45

11 Denominator Use a denominator that is meaningful to your institution and / or the treatment protocol. Denominators = 1. Total White Blood Cells - CD45 pos 2. Total Nucleated Cells (TNC) - DNA stain, includes NRBC 3. Mononuclear cells (MNC) - DNA stain, includes NRBC 0.019% of CD % of TNC 0.011% of MNC

12 Denominator High regenerating myeloid cells affecting MRD % 0.40% of CD % of TNC 1.99% of MNC Molecular MRD = 0.6% (frozen) High NRBC affecting MRD % 0.05% of CD % of MNC 0.009% of TNC

13 Normal Template: Tube 1

14 Normal Template: Tube 2

15 Results n = 261 patients (15 adults), >750 MRD tests Day 8: 84% MRD positive (> 0.01%), 27% at a level >1% Day 29: 30% MRD positive (> 0.01%) This agrees well with the reported level of positivity in the literature.

16 Results Most positive cases showed a discrete cluster of at least 20 abnormal cells. 245/261 (94%) patients had aberrant phenotypes that could be distinguished from normal haematogones 9 patients are now being monitored post bone marrow transplant. 1 patient is enrolled on a clinical trial involving CAR T cells due to a positive MRD at day 8, 29 and end of consolidation therapy combined with unfavourable cytogenetics.

17 patient Day 8 MRD% Day 29 MRD % End consolidation MRD % Results Transplant patients Reason for Transplant poor cyto(mll t(4;11), MRD+, matched sib 2 NT NT NT Relapse post 1 st BMT (6.5& 20.8) (0.09) 3.99 (20& 55.9) NT HR, poor cyto (BCR-ABL) Relapse, matched sib Pre BMT MRD % Day 60 MRD% Day 100 MRD % (pos <0.005) 0.01 (0.0009) HR, Relapse HR, poor cyto (near haploid) matched sib (75.1) (35 &22.5) HR, poor cyto (BCR-ABL), poor response 8 NT NT NT Relapse, matched rel CSF relapse, poor cyto (BCR-ABL) 0.32 (2 & 1.1) (pos <0.001 <0.16 (insuff.) (pos<0.005 & 0.00) (pos <0.005) pending (Neg& 0.0%) (pos ) Day 200 MRD % 1 year MRD % NT 0.04 (0.02) (Neg& 0.0%) D132 Relapsed pending pending

18 Correlations Flow Cytometry N=125 COG enrolled patients (direct comparison with COG flow cytometry data) N=119 Day 8 data pairs 109 in agreement (pos or neg at 0.01% cut off, or clinically significant cut off of >1%) 10 (7 reviewed to agree) discrepant (RCH >0.01%, COG % or RCH>1%, COG <1%) 109/119, 92% concordance N=118 Day 29 data pairs 109 in agreement (pos or neg at 0.01% cut off) 9 (9 reviewed to agree) discrepant (RCH >0.01%, COG %) 109/118, 92% concordance 9 patients have changed risk groups and treatment based on the RCH result.

19 Day 8 Correlations with COG Flow Cytometry Results % of abnormal cells detected by RCH R² = % of abnormal cells detected by COG % of abnormal cells detected by RCH Removing 3 outliers 3 outliers (>20% (>20% MRD) MRD) % of abnormal cells detected by COG

20 Day 29 Correlations with COG Flow Cytometry Results % of abnormal cells detected by RCH R² = % of abnormal cells detected by COG % of abnormal cells detected by RCH Removing 2 outliers Removing (>0.25%) 4 outliers (>1% MRD) % of abnormal cells detected by COG

21 Correlations Molecular N=101 Day 29 and post consolidation comparison with molecular results 98 in agreement (pos or neg at 0.01% cut off) 3 discrepant (1 flow cytometry neg, molecular pos) 98/101, 97% concordance 2 flow cytometry pos, molecular neg

22 Correlations with Molecular Results % of abnormal cells detected by molecular R² = % of abnormal cells detected by Molecular Removing 4 high % MRD outliers % of abnormal cells detected by flow cytometry % of abnormal cells detected by flow cytometry

23 Conclusion What lessons have we learnt? It takes time to become experienced It is worth taking the time to set up a robust panel and maintaining a high level of quality control. Robust, rapid, cost effective We are giving all our patients the benefit of MRD based risk stratification of their treatment. Enables accurate monitoring post transplant to tailor immunosuppressive therapy. Challenges Anti-CD19 therapies

24 Acknowledgements Cell Therapy and Flow Cytometry Laboratory Michael Swain Domenic Fernandez Julia Schulz Matthew Archer Haematologists Janine Campbell Helen Savoia Children s Cancer Centre, RCH Francoise Mechinaud COG Data manager, RCH Allison Lamb Angie Cutajar Brenton Ward Lyn Verkerk COG reference laboratory Brent Wood Katy Dough

ETP - Acute Lymphoblastic Leukaemia

ETP - Acute Lymphoblastic Leukaemia ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently

More information

ACUTE LYMPHOBLASTIC LEUKEMIA

ACUTE LYMPHOBLASTIC LEUKEMIA ACUTE LYMPHOBLASTIC LEUKEMIA YOUNG ADULT PATIENT Highlights clonoseq Tracking (MRD) Testing in the peripheral blood revealed early signs of relapse post-transplant Patient achieved remission after CAR-T

More information

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine

Do Your Flow Cytometric LDTs. Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine Do Your Flow Cytometric LDTs Conform to the ICSH ICCS Validation Guidelines? Fiona E. Craig, MD University of Pittsburgh School of Medicine How should LDTs be validated? Accuracy Specificity Sensitivity

More information

MRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome

MRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host

More information

Children ALL MRD study according to protocol of D. Campana

Children ALL MRD study according to protocol of D. Campana Children ALL MRD study according to protocol of D. Campana L.Yu. Grivtsova Laboratory of Haematopoiesis Immunology State N.N.Blokhin Russian Cancer Research Center affiliated to the Russian Academy of

More information

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX

Case 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME

More information

Flow cytometry leukocyte differential : a critical appraisal

Flow cytometry leukocyte differential : a critical appraisal Flow cytometry leukocyte differential : a critical appraisal Francis Lacombe Flow cytometry department University Hospital of Bordeaux, Pessac, France francis.lacombe@chu-bordeaux.fr 2008 HORIBA ABX, All

More information

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow

NUMERATOR: Patients who had baseline cytogenetic testing performed on bone marrow Quality ID #67 (NQF 0377): Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow National Quality Strategy Domain: Effective Clinical Care

More information

Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance

More information

DURACLONE IF BE CERTAIN ABOUT THE RESPONSE. l res. a il n c n. For Research Use Only - Not for use in Diagnostic procedures

DURACLONE IF BE CERTAIN ABOUT THE RESPONSE. l res. a il n c n. For Research Use Only - Not for use in Diagnostic procedures DURACLONE IF earch tria l res lc a om ic il n c n nio pa Yo ur BE CERTAIN ABOUT THE RESPONSE For Research Use Only - Not for use in Diagnostic procedures BE CERTAIN ABOUT THE RESPONSE The sensitive and

More information

Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD

Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Is Transplant a Necessity or a Choice: Focus on the necessity for CR and MRD Ajai Chari, MD Associate Professor of Medicine Director of Clinical Research Multiple Myeloma Program Mount Sinai Medical Center

More information

Hematology MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL*

Hematology MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL* Hematology FREQUENCY OF ABERRANT EXPRESSION OF CD MARKERS IN CASES OF ACUTE LEUKEMIA MUHAMMAD M. KHURRAM* SAGHIR A. JAFRI* ABDUL MANNAN** AFTAB NADEEM*** ASIF JAMAL* SUMMARY: In the present study 100 patients

More information

MUD SCT for Paediatric AML?

MUD SCT for Paediatric AML? 7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old

More information

N Engl J Med Volume 373(12): September 17, 2015

N Engl J Med Volume 373(12): September 17, 2015 Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most

More information

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies

Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies Malaysian J Pathol 2004; 26(2) : 111 116FLOW CYTOMETRY MYELOPEROXIDASE DETECTION Comparison of myeloperoxidase detection by flow cytometry using two different clones of monoclonal antibodies CF Leong MPath,

More information

Multiparameter flow cytometry can be used to

Multiparameter flow cytometry can be used to Minimal residual disease testing in Acute Leukemia Anjum Hassan MD Assistant Professor of Pathology and Immunology, Director FISH laboratory in Anatomic Pathology, Washington University in St Louis, School

More information

Timing and complications of allogeneic stem cell transplant in Ph + ALL

Timing and complications of allogeneic stem cell transplant in Ph + ALL Timing and complications of allogeneic stem cell transplant in Ph + ALL Dr Ashlea Campbell Haematology Advanced Trainee Concord Repatriation and General Hospital Royal Prince Alfred Hospital 24 th Feb

More information

Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010

Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related

More information

Myeloma Support Group: Now and the Horizon. Brian McClune, DO

Myeloma Support Group: Now and the Horizon. Brian McClune, DO Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?

More information

Successful flow cytometric immunophenotyping of body fluid specimens

Successful flow cytometric immunophenotyping of body fluid specimens Successful flow cytometric immunophenotyping of body fluid specimens Fiona E. Craig, MD Division of Hematopathology Mayo Clinic Arizona 2017 MFMER slide-1 Financial disclosure No conflicts 2017 MFMER slide-2

More information

Original article. Key words: Lymphoblastic leukemia, Acute, Childhood, Minimal residual disease, Flow cytometry

Original article. Key words: Lymphoblastic leukemia, Acute, Childhood, Minimal residual disease, Flow cytometry Original article DOI: 10.5/kjp.2010.5.11.957 Korean J Pediatr 2010;5(11):957-96 Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction

More information

Optimizing Intracellular Flow Cytometry

Optimizing Intracellular Flow Cytometry Optimizing Intracellular Flow Cytometry Detection of Cytokines, Transcription Factors, and Phosphoprotein by Flow Cytometry Presented by Erika O Donnell, PhD, BD Biosciences 23-14876-00 Outline Basic principles

More information

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question

Clinical question. Screening tube. Diagnostic panel MRD. Clinical question OW CYTOMETRY UPDATES IN LYMPHOPROLIFERATIVE DISORDERS CANCER RESEARCH CENTER IBSAL UNIVERSITY & UNIVERSITY HOSPITAL, SALAMANCA (SPAIN) DISCLOSURES The EuroFlow Scientific Consortium Iamco-chairof receives

More information

G-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics

G-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics Journal of Physics: Conference Series PAPER OPEN ACCESS G-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics To cite

More information

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions

More information

Naive, memory and regulatory T lymphocytes populations analysis

Naive, memory and regulatory T lymphocytes populations analysis Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis

More information

Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010

Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale

More information

CARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital

CARE at ASH 2014 Leukemia. Julie Bergeron, MD Maisonneuve-Rosemont Hospital CARE at ASH 2014 Leukemia Julie Bergeron, MD Maisonneuve-Rosemont Hospital Acute Leukemias Dr. Julie Bergeron Hôpital Maisonneuve-Rosemont, Montréal Disclosures Advisory boards in 2014: AMGEN EUSA pharma

More information

DuraClone IM. Standardized phenotyping panels for studies of the human immune system

DuraClone IM. Standardized phenotyping panels for studies of the human immune system DuraClone IM Standardized phenotyping panels for studies of the human immune system Standardize with the experts, adopt DuraClone IM Tubes. Clinical research studies require accurate, reproducible results

More information

MRD in CML (BCR-ABL1)

MRD in CML (BCR-ABL1) MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:

More information

Enumeration of HSCs. Stem cell evaluation methods: Why we need a reliable method. André Tichelli

Enumeration of HSCs. Stem cell evaluation methods: Why we need a reliable method. André Tichelli Enumeration of HSCs Stem cell evaluation methods: Why we need a reliable method. André Tichelli 1 The aim for this presentation At the end of this presentation you should know What the clinician needs

More information

Leukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto

Leukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et

More information

Fluorochrome Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 CTLA-4 CTLA-4 CD15 CD3 FITC. Bio) PD-1 (MIH4, BD) ICOS (C398.4A, Biolegend) PD-L1 (MIH1, BD)

Fluorochrome Panel 1 Panel 2 Panel 3 Panel 4 Panel 5 CTLA-4 CTLA-4 CD15 CD3 FITC. Bio) PD-1 (MIH4, BD) ICOS (C398.4A, Biolegend) PD-L1 (MIH1, BD) Additional file : Table S. Antibodies used for panel stain to identify peripheral immune cell subsets. Panel : PD- signaling; Panel : CD + T cells, CD + T cells, B cells; Panel : Tregs; Panel :, -T, cdc,

More information

WHAT IS MY MRD STATUS?

WHAT IS MY MRD STATUS? Measurable Residual Disease WHAT IS MY MRD STATUS? Each patient case is different and your results may vary. Always talk with your doctor about whether any test is right for you, what the results mean,

More information

Test Name Results Units Bio. Ref. Interval. Positive

Test Name Results Units Bio. Ref. Interval. Positive LL - LL-ROHINI (NATIONAL REFERENCE 135091533 Age 28 Years Gender Male 1/9/2017 120000AM 1/9/2017 105415AM 4/9/2017 23858M Ref By Final LEUKEMIA DIAGNOSTIC COMREHENSIVE ROFILE, ANY 6 MARKERS t (1;19) (q23

More information

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia

Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Acute Myeloid Leukemia Articles Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia Bruno C. Medeiros, 1 Megan Othus, 2,3 Min Fang, 3,4 Frederick R. Appelbaum,

More information

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back...

Case #16: Diagnosis. T-Lymphoblastic lymphoma. But wait, there s more... A few weeks later the cytogenetics came back... Case #16: Diagnosis T-Lymphoblastic lymphoma But wait, there s more... A few weeks later the cytogenetics came back... 46,XY t(8;13)(p12;q12)[12] Image courtesy of Dr. Xinyan Lu Further Studies RT-PCR

More information

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish

More information

Ferrata Storti Foundation

Ferrata Storti Foundation Published Ahead of Print on November 30, 2009, as doi:10.3324/haematol.2009.018911. Copyright 2009 Ferrata Storti Foundation. Early Release Paper Enhanced sensitivity of flow cytometry for routine assessment

More information

Initial Diagnostic Workup of Acute Leukemia

Initial Diagnostic Workup of Acute Leukemia Initial Diagnostic Workup of Acute Leukemia Guideline from the College of American Pathologists (CAP) and the American Society of Hematology (ASH) Publication: Archives of Pathology and Laboratory Medicine

More information

Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review

Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University

More information

Oncology Genetics: Cytogenetics and FISH 17/09/2014

Oncology Genetics: Cytogenetics and FISH 17/09/2014 Oncology Genetics: Cytogenetics and FISH 17/09/2014 Chris Wragg Head of Oncology Genomics, BGL BGL Bristol Genetics Laboratory (BGL) CPA accredited Genetics laboratory serving a core population of 4-5million

More information

Victorian Paediatric Oncology Situational Analysis & Workforce Requirements

Victorian Paediatric Oncology Situational Analysis & Workforce Requirements - Victorian Paediatric Oncology Situational Analysis & Workforce Requirements 2012-2026 SUMMARY REPORT May 2013 1 Contents Executive summary...3 1. Introduction...6 2. Project method...8 2.1 Estimating

More information

Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia

Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI

More information

Test Utilization: Chronic Lymphocytic Leukemia

Test Utilization: Chronic Lymphocytic Leukemia Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.

More information

Hematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

Hematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy Hematology Measure #2: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy This measure may be used as an Accountability measure Clinical Performance

More information

The Practical Application of Statistics: Reading papers and interpreting clinical studies...

The Practical Application of Statistics: Reading papers and interpreting clinical studies... The Practical Application of Statistics: Reading papers and interpreting clinical studies... Richard Szydlo Imperial College / Hammersmith Hospital, London Karlskirche Evaluating new treatments

More information

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000

More information

Disclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:

Disclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures: Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,

More information

Circulating Endothelial Cells and Their Clinical Significance Jaco Kraan

Circulating Endothelial Cells and Their Clinical Significance Jaco Kraan Circulating Endothelial Cells and Their Clinical Significance Jaco Kraan Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam, The Netherlands ISLH 2016 - Milano, Italy Financial disclosure

More information

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy

Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy New Evidence reports on presentations given at ASH 2009 Improving Response to Treatment in CLL with the Addition of Rituximab and Alemtuzumab to Chemoimmunotherapy From ASH 2009: Chronic Lymphocytic Leukemia

More information

HD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients -

HD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients - HD-SNP Microarray Analysis of the Study 9 High Risk ALL Patients - Increased Yield of Important Prognostic Information Nadine K Berry 1,2,4, Rodney J. Scott 1,4, Rosemary Sutton 5, Toby N Trahair 5, Philip

More information

VALORE PROGNOSTICO DEL GENOTIPO NPM1 MUTATO/FLT3-ITD NEGATIVO ED ELEVATI LIVELLI DI APOPTOSI SPONTANEA DETERMINATI IN CITOMETRIA A FLUSSO NELLA LAM

VALORE PROGNOSTICO DEL GENOTIPO NPM1 MUTATO/FLT3-ITD NEGATIVO ED ELEVATI LIVELLI DI APOPTOSI SPONTANEA DETERMINATI IN CITOMETRIA A FLUSSO NELLA LAM VALORE PROGNOSTICO DEL GENOTIPO NPM1 MUTATO/FLT3-ITD NEGATIVO ED ELEVATI LIVELLI DI APOPTOSI SPONTANEA DETERMINATI IN CITOMETRIA A FLUSSO NELLA LAM G. Del Poeta Dept of Hematology,, University Tor Vergata

More information

Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting

Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting Peer reviewed ORIGINAL ARTICLE Retrospective data analysis of all requests for flow cytometric immunophenotyping in a tertiary hospital setting A Prinsloo MSc J Nel MMed (Haem) R Pool MMed (Haem) Tshwane

More information

New IMWG Response Criteria

New IMWG Response Criteria New IMWG Response Criteria Shaji Kumar, M.D. Professor of Medicine Division of Hematology Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo

More information

Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08)

Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Department of Pediatric Hematology/Oncology King Fahd National Centre for Children s Cancer and Research King Faisal Specialist Hospital and

More information

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain

Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531

More information

Supporting Information

Supporting Information Supporting Information Idoyaga et al. 10.1073/pnas.0812247106 SSC a) Single cell suspension 99 Aqua b) Live cells 96 -W c) Singlets 92 -A CD19+ER119 d) CD19 ER119 cells 97 CD3 e) CD3 cells 27 f) DX5 cells

More information

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful

More information

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE Naynesh Kamani, M.D. Children s National Medical Center GW University School of Medicine Washington, DC SCD scope of problem in USA Commonest

More information

Philadelphia-positive Acute Lymphoblastic Leukemia

Philadelphia-positive Acute Lymphoblastic Leukemia Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,

More information

Adam S. Coleman, Ph.D.

Adam S. Coleman, Ph.D. The Challenges of Severe Combined Immunodeficiency Screening in a Two Screen State 9/13/2017 Laboratories Administration 73,000 births annually 2 sample state for NBS Adam S. Coleman, Ph.D. Supervisor,

More information

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital

Minimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical

More information

The Past, Present, and Future of Acute Myeloid Leukemia

The Past, Present, and Future of Acute Myeloid Leukemia The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review

More information

Flow Cytometry: useful method to less invasive diagnosis in pediatric lymphomas

Flow Cytometry: useful method to less invasive diagnosis in pediatric lymphomas Flow Cytometry: useful method to less invasive diagnosis in pediatric lymphomas Prof. Elaine Sobral da Costa Universidade Federal do Rio de Janeiro UFRJ Fac. Medicina - Departamento de Pediatria elainesc.ufrj@gmail.com

More information

Application Note. Productivity and Efficiency of 6-Color BD Multitest and BD Trucount Technologies for Enumeration of Lymphocyte Subsets

Application Note. Productivity and Efficiency of 6-Color BD Multitest and BD Trucount Technologies for Enumeration of Lymphocyte Subsets Sept 27 Productivity and Efficiency of 6-Color BD Multitest and BD Trucount Technologies for Enumeration of Lymphocyte Subsets Phillip Ruiz, MD, PhD*, Michael J. Borowitz, MD, PhD**, Henok Tilahun***,

More information

Haplo vs Cord vs URD Debate

Haplo vs Cord vs URD Debate 3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor

More information

Can we classify cancer using cell signaling?

Can we classify cancer using cell signaling? Can we classify cancer using cell signaling? Central hypotheses (big ideas) Alterations to signaling genes would cause leukemic cells to react in an inappropriate or sensitized manner to environmental

More information

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION V O L U M E 2 6 N U M B E R 1 8 J U N E 2 0 2 0 0 8 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With

More information

Challenges in Development and Validation of an Intracellular Cytokine Staining assay

Challenges in Development and Validation of an Intracellular Cytokine Staining assay Challenges in Development and Validation of an Intracellular Cytokine Staining assay Jenny Hendriks, Crucell Hatching @ EBF, Brussels, June 202 www.crucell.com Vaccines vs Protein therapeutics Protein

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2

More information

Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning

Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose

More information

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail

More information

MHC MULTIMER PROFICIENCY PANEL 2017

MHC MULTIMER PROFICIENCY PANEL 2017 MHC MULTIMER PROFICIENCY PANEL 2017 August 2017 CONTACT Charlotte Halgreen ProficiencyPanel@immudex.com FOR MORE INFORMATION www.proficiencypanel.com MHC MULTIMER PROFICIENCY PANEL 2017 This report summarizes

More information

Flow Cytometric Applications for Immunotherapy of Cancer

Flow Cytometric Applications for Immunotherapy of Cancer Flow Cytometric Applications for Immunotherapy of Cancer Bone Marrow Transplantation and Cellular Therapy Program and Divisions of Neuro-oncology and Neurosurgery University of Alabama at Birmingham Basic

More information

Reference: NHS England 1602

Reference: NHS England 1602 Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC

More information

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell

More information

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017 LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer

More information

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines

Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines Lynn B. Bonifacio, MD, FPCP, DPSHBT National Kidney and Transplant Institute Philippines 3. WBMT Workshop 14-15 November 2014 Cape Town, South Africa Department for Hematology and Medical Oncology Leipzig,

More information

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,

More information

Hematopathology Case Study

Hematopathology Case Study www.medfusionservices.com Hematopathology Case Study CV3515-14 JUNE Clinical Presentation: Clinical Information: A 42 year old male with history of chronic myelogenous leukemia (CML) presents with an elevated

More information

Optimizing Intracellular Flow Cytometry:

Optimizing Intracellular Flow Cytometry: Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors Presented by Jurg Rohrer, PhD, BD Biosciences 23-10780-00 Outline Introduction Cytokines Transcription

More information

Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia

Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia Pollyea DA 1, Tallman MS 2,3, de Botton S 4,5, DiNardo CD 6, Kantarjian HM

More information

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability

More information

Application Information Bulletin: Cell Signaling

Application Information Bulletin: Cell Signaling Application Information Bulletin: Cell Signaling Detection of Both Surface Proteins and Intracellular Phospho-Determinants in Whole Blood Using the PerFix-p Reagent System William L. Godfrey 1, Li Yang

More information

Hematology Unit Lab 2 Review Material

Hematology Unit Lab 2 Review Material Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided

More information

Molecular Advances in MDS. Alexey Aleshin MD, MBA Medical Oncology Fellow Stanford University

Molecular Advances in MDS. Alexey Aleshin MD, MBA Medical Oncology Fellow Stanford University Molecular Advances in MDS Alexey Aleshin MD, MBA Medical Oncology Fellow Stanford University Learning Objectives Next Generation Sequencing MDS Genomics Hereditary MDS Future Directions Genes, Genomes,

More information

Cell sorting: A bridge between morphology and flow cytometry. Pr François Mullier, Pr Bernard Chatelain July 19th, 2013

Cell sorting: A bridge between morphology and flow cytometry. Pr François Mullier, Pr Bernard Chatelain July 19th, 2013 Cell sorting: A bridge between morphology and flow cytometry Pr François Mullier, Pr Bernard Chatelain July 19th, 2013 1 CELL SORTING: PRINCIPLES D.Davies CELL SORTING: PRINCIPLES Aims Efficiency Purity

More information

Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types

Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Acute Lymphocytic Leukemia Early Detection, Diagnosis, and Types Detection and Diagnosis Catching cancer early often allows for more treatment options. Some early cancers may have signs and symptoms that

More information

Acute myeloid leukemia

Acute myeloid leukemia Acute myeloid leukemia the molecular pathogenesis Pr Violaine Havelange, MD, PhD Hematological department Acute myeloid leukemia (AML) Incidence : 3-5 cases/100.000 population 80% of acute leukemias in

More information

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco

Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo

More information

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British

More information

Summary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):

Summary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5): Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical

More information

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls

Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,

More information

ADRL Advanced Diagnostics Research Laboratory

ADRL Advanced Diagnostics Research Laboratory ADRL Advanced Diagnostics Research Laboratory John DeCoteau, MD FRCP Department of Pathology, Division of Hematopathology University of Saskatchewan Saskatchewan Cancer Agency ADRL Project Objectives New

More information

An Introduction to Bone Marrow Transplant

An Introduction to Bone Marrow Transplant Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,

More information

Flow Cytometry Applications in Hematological Diseases. Case Study. Sa A. Wang, MD Dept. of Hematopathology UT MD Anderson Cancer Center

Flow Cytometry Applications in Hematological Diseases. Case Study. Sa A. Wang, MD Dept. of Hematopathology UT MD Anderson Cancer Center Flow Cytometry Applications in Hematological Diseases Case Study Sa A. Wang, MD Dept. of Hematopathology UT MD Anderson Cancer Center ASCP 2011, Las Vegas Objectives Using case presentation format to illustrate

More information